Shaanxi Xuang Biopharmaceutical

Shaanxi Xuang Biopharmaceutical is a China-based biotechnology company focused on the development of innovative therapeutics for metabolic and endocrine disorders. The company's lead program, MT1013, is a first-in-class dual-targeting peptide agonist that simultaneously acts on the calcium-sensing receptor (CaSR) and the osteogenic growth peptide (OGP) receptor. This candidate is primarily being developed for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease. Shaanxi Xuang Biopharmaceutical leverages its expertise in peptide engineering to create multi-functional molecules that address complex disease pathways. The company maintains strategic collaborations to advance its clinical pipeline and expand its commercial reach within the Asian market.